Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFO5W3
|
|||
| Drug Name |
MK-4621
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid-inducible gene-1 (RIG-1) | Target Info | Agonist | [2] |
| KEGG Pathway | NF-kappa B signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| Epstein-Barr virus infection | ||||
| Reactome | ISG15 antiviral mechanism | |||
| TRAF3-dependent IRF activation pathway | ||||
| TRAF6 mediated IRF7 activation | ||||
| TRAF6 mediated NF-kB activation | ||||
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | ||||
| Negative regulators of RIG-I/MDA5 signaling | ||||
| WikiPathways | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03739138) Intratumoral/Intralesional Administration of MK-4621/JetPEI With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002). U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name RGT100). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.